Loading...
Loading...
ACOR| Name | Value |
|---|---|
| Revenues | 31.1M |
| Cost of Revenue | 8.8M |
| Gross Profit | 22.3M |
| Operating Expense | 39.3M |
| Operating I/L | -17.0M |
| Other Income/Expense | -3.1M |
| Interest Income | 0.0M |
| Pretax | -20.1M |
| Income Tax Expense | 26.6M |
| Net Income/Loss | -46.7M |
Acorda Therapeutics, Inc. is a biopharmaceutical company specializing in developing and commercializing therapies for neurological disorders. The company's primary revenue-generating products include Ampyra (dalfampridine), an oral drug that enhances walking ability in multiple sclerosis patients, and Inbrija, used to treat OFF periods in Parkinson's disease. Additionally, Acorda markets Ampyra as Fampyra in various regions. The company also focuses on developing ARCUS for acute migraine treatment, rHIgM22 for multiple sclerosis, and Cimaglermin alfa for heart failure patients. Acorda Therapeutics, Inc. has a collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra.
